A total of 752 patients were included in the modified intent-to-treat (mITT) population (n = 379, etanercept 50 mg BIW/QW; n = 373, etanercept 50 mg QW/QW). Baseline demographics and ...

Patients who did not respond to treatment with etanercept in the initial 12-week period were subsequently treated with 90 mg ustekinumab at weeks 16 and 20; 49% of these patients achieved a PASI ...

Methods: Participants (N = 752) were randomized to receive etanercept 50 mg twice weekly (BIW; n = 379) or 50 mg once weekly (QW; n = 373) for 12 weeks by subcutaneous injection.